GlassScriptPhysician profile
Tabitha R Barnard
NPI 1366944282
$1,371.25
in general payments reported to CMS, 2019-2025
28 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $968 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $402.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $213.16 | 2021-2025 | |
| Novo Nordisk INC | $211.99 | 2021-2025 | Wegovy, Ozempic |
| Astellas Pharma US INC | $122.37 | 2021-2025 | Veozah |
| Pfizer INC. | $87.32 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $68.98 | 2021 | |
| Amarin Pharma, INC. | $67.03 | 2021 | |
| Lilly USA, LLC | $63.85 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $52.03 | 2021-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $47.14 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $43.77 | 2021-2025 | Airsupra |
| Amgen INC. | $42.38 | 2021 | |
| Ironwood Pharmaceuticals, INC | $36.25 | 2021 | |
| Janssen Pharmaceuticals, INC | $35.97 | 2021 | |
| Merck Sharp & Dohme LLC | $28.64 | 2021 | |
| Nestle Healthcare Nutrition INC. | $27.40 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $27.24 | 2025 | Eterna |
| E.R. Squibb & Sons, L.L.C. | $23.80 | 2021 | |
| Glaxosmithkline, LLC. | $22.14 | 2021 | |
| Inspire Medical Systems, INC. | $18.83 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.15 | 2021 | |
| Axsome Therapeutics, INC. | $16.46 | 2025 | Auvelity |
| Genentech USA, INC. | $16.31 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.10 | 2021 | |
| Antares Pharma, INC. | $15.23 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.66 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.62 | 2021 | |
| Mylan Specialty L.P. | $11.82 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Barnard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.